Regulators have tended to ignore this sort of issue and it may well be generic to a number of network-based industries with committed costs.
Epileptics report a range of side-effects, some of them severe, when they are switched from a branded to a generic anti-epileptic drug (AED) or switched from one generic to another.
FORBES: FDA Needs To Address Concerns Over Generic Drug Equivalence
Pfizer reached a settlement that enabled Actavis and a second company to sell slightly cheaper generic versions starting Nov. 30, 2011 and several other generic drugmakers to begin selling generic Lipitor six months later.
Now clearly with drug companies we have to do more to get generic drugs to market, including the new biologics that are coming into the marketplace and are often extremely expensive.
It seems that the best way to prosper in the competitive world of generic drugs is to get less generic.
The practice involves pharmaceutical manufacturers paying generic manufacturers to delay the release of a generic drug in anticipation of the patent cliff.
The move came just before the U.S. Department of Justice announced it would appeal an order by Korman requiring drugstores to sell both Plan B and cheaper generic alternatives to women of any age.
In general, composition-of-matter lawsuits are considered harder to win than other avenues of attack employed by generic drugmakers to hack away at the thicket of patents that guard blockbuster medicines.
Gopal Dabade of All India Drug Action Network, an India-based non-profit group that works for access to essential medicines, said the ruling will allow Indian generic manufacturers to continue to supply Indians and consumers in other developing countries with cheap medicines.
So they offer to settle with the generic manufacturer, allowing them to sell a generic version beginning in March 2012.
The Petitioners asked the Court to review whether federal antitrust laws prohibit the settlement of patent litigation between a branded drug maker and a generic drug company which include a financial incentive for the generic company to hold off marketing its product for a time period.
FORBES: Campaign Against 'Pay-for-Delay' Drug Patent Settlements Suffers Setback at Supreme Court
To generic drug makers, some physicians and Wall Street analysts, however, the moves amounted to a transparent one-two punch designed to delay lower-cost generic tablets from reaching the market.
FORBES: Reckitt's Suboxone Strategy Is Really About Patients Or Profits?
The Obama administration wants Big Pharma to stop paying generic drug competitors to delay releasing cheaper versions of brand-name drugs.
Analysts widely expect the generic firms to lose, but even experts have trouble calling patent cases.
If a generic were to get through, a big chunk of Provigil's sales would vanish.
Eventually the corporate police stamped out errant behavior and insisted on generic projects to please everyone.
Lilly has lost patent cases on several big sellers that will enable generic versions to launch sooner.
Both companies identified the increased proliferation of generic drugs to be a major contributor to the decline.
Many pharmaceutical companies are struggling as expiring patents allow cheap generic drugs to gnaw away at their sales.
The Arizona Republican would also permit generic drugs to be imported from Canada to increase competition among pharmaceutical manufacturers.
Generic competition to Topamax and Risperdal cut into sales, but strong growth from inflammatory disease treatment Remicade helped moderate the damage.
Pfizer is also offering Lipitor for a generic price to big firms such as Medco, which manage health schemes' prescription costs.
In each instance, Gray pushes a generic situation to an expressionistic crisis point -- and Bobby forfeits another ounce of his humanity.
Soon-Shiong, a surgeon who made his initial riches selling generic drugs to hospitals, has always insisted that the drug was more than just side-effect-sparing.
They win if the judge would have ruled for Forbes, because the settlement allows generic drugs to appear earlier than they would have normally.
Is there a generic alternative to the medicine you're prescribing me?
If there's no exact generic equivalent to the brand-name drug that you are taking, there may be similar drugs in the same class that are close enough.
But extending the patent would be a political liability for legislators since the move to a generic drug is likely to save consumers (and insurance companies) hundreds of millions.
U.S. law in many cases gives the first generic company to get approval for a particular copycat drug six months of exclusivity, creating a duopoly between the original brand and the new generic.
Morningstar pharmaceutical-industry analyst Damien Conover estimates that Pfizer can expect generic competition to undercut gains from new drugs, to the point that sales will grow by just 1% a year on average going forward.
应用推荐